Tivozanib: current status and future directions in the treatment of solid tumors.

Abstract

INTRODUCTION:

Tivozanib is a novel tyrosine kinase inhibitor (TKI) which inhibits vascular endothelial growth factor (VEGF) receptors-1, -2, and -3 at nanomolar concentrations.

AREAS COVERED:

A comprehensive MEDLINE and American Society of Clinical Oncology abstract search was performed to gather all relevant clinical and translational data related to tivozanib. We discuss pre-clinical studies associated with tivozanib, and the results of a Phase I assessment in advanced solid tumors. We highlight combination studies with tivozanib, including pairings of tivozanib with cytotoxic therapy in patients with colorectal cancer and breast cancer. A randomized discontinuation Phase II study and a randomized Phase III study assessing the activity of tivozanib in metastatic renal cell carcinoma (mRCC) are described in detail.

EXPERT OPINION:

Tivozanib will face the challenge of entering an already crowded therapeutic space in mRCC-emerging combination studies and biomarker assessments may distinguish this agent among other VEGF-TKIs. The current review will outline the development pathway of tivozanib to date, and offer lessons learned and future opportunities.

• Authors: Sumanta K Pal, Paulo G Bergerot, Robert A Figlin
• Journal: Expert opinion on investigational drugs (Expert Opin Investig Drugs) Vol. 21 Issue 12 Pg. 1851-9 (Dec 2012) ISSN: 1744-7658 [Electronic] England
• PMID: 23013465 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Review)

Chemical References

• Antineoplastic Agents
• Phenylurea Compounds
• Quinolines
• tivozanib
• Receptors, Vascular Endothelial Growth Factor

Topics

• Animals
• Antineoplastic Agents (pharmacology, therapeutic use)
• Humans
• Neoplasms (drug therapy)
• Phenylurea Compounds (pharmacology, therapeutic use)
• Quinolines (pharmacology, therapeutic use)
• Receptors, Vascular Endothelial Growth Factor (antagonists & inhibitors)